Tesamorelin
low riskAlso: Egrifta · Egrifta SV · TH9507
Tesamorelin is the only FDA-approved GHRH analog, approved for visceral adiposity in HIV patients. Phase II trials ongoing for NASH in the general population. Well-tolerated with clear clinical evidence.
Reported Benefits
Visceral fat reduction (HIV)
Phase III: ~15% visceral fat reduction vs. placebo. FDA-approved indication.
NASH / liver fat reduction
Phase II (Stanley 2014): significant liver fat reduction and metabolic improvement.
Cognitive function (elderly)
Small trials suggest executive function improvement via IGF-1 elevation.
Mechanism of Action
GHRH analog — stimulates pulsatile GH secretion, increasing IGF-1 and reducing visceral fat accumulation via GH's lipolytic effects.
Key Clinical Studies
Only FDA-Approved GHRH Analog
Tesamorelin is unique — the only GHRH analog with FDA approval. The HIV lipodystrophy approval provides a regulatory precedent for GHRH-based therapy with implications for the broader metabolic disease pipeline.
✦ Sponsored
Stop Guessing About Your Health. Start Optimizing It.
Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.
Learn More →
Regulatory Status
FDA ApprovedFDA approved as Egrifta SV for HIV-associated lipodystrophy
Safety Profile
Side Effects
- •Injection site reactions
- •Fluid retention
- •Arthralgias
- •Glucose elevation (monitor)
Contraindications
- •Active malignancy
- •Pituitary disease
- •Pregnancy
Drug Interactions
- •Glucocorticoids
- •Insulin
Primary Uses
Related Peptides
Used For
Planning a protocol?
Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Tesamorelin?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →